GlassScriptPhysician profile
Kabir K Das
NPI 1699955377
$2,749.03
in general payments reported to CMS, 2019-2025
27 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $457 · 2021: $568 · 2022: $265 · 2023: $208 · 2024: $218 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.49 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $512.36 | 2019-2024 | Veozah |
| Pfizer INC. | $385.68 | 2019-2025 | |
| Novo Nordisk INC | $270.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $239.75 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $226.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.23 | 2019-2021 | |
| Lilly USA, LLC | $105.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.27 | 2021-2023 | Tradjenta, Synjardy, Jardiance |
| Abbott Laboratories | $83.50 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $80.23 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $78.40 | 2021-2025 | Minimed 780g |
| Abbvie INC. | $72.09 | 2020-2022 | |
| Glaxosmithkline, LLC. | $63.42 | 2021-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.00 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $43.19 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $38.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.43 | 2019-2022 | |
| Boston Scientific Corporation | $34.97 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $32.17 | 2019-2020 | |
| Smith+Nephew, INC. | $27.60 | 2021-2022 | |
| Genentech USA, INC. | $27.51 | 2019-2020 | |
| Allergan, INC. | $24.49 | 2020 | |
| Shire North American Group INC | $22.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.77 | 2025 | |
| Globus Medical, INC. | $19.59 | 2025 | Senza |
| Ironwood Pharmaceuticals, INC | $12.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kabir Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.